06.10.15
Richard Tullis, M.D., has resigned from the board of San Diego, Calif.-based Aethlon Medical Inc. in order to support the company’s application to list on the Nasdaq capital market. Nasdaq corporate governance rules state that a listed company’s board of directors is required to have a majority of independent directors. Prior to the resignation of Tullis, Aethlon’s board was comprised of an equal number of inside and outside directors. Tullis will continue in his position as the company’s chief science officer.
Aethlon previously disclosed that it had submitted an application to Nasdaq to request that its common stock be approved for listing on the Nasdaq capital market. Nasdaq has not yet approved the company’s listing application.
“I have enjoyed my role as a director over the years at Aethlon Medical and look forward to continuing to contribute to the company in my ongoing position as chief science officer,” Tullis said.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases
Aethlon previously disclosed that it had submitted an application to Nasdaq to request that its common stock be approved for listing on the Nasdaq capital market. Nasdaq has not yet approved the company’s listing application.
“I have enjoyed my role as a director over the years at Aethlon Medical and look forward to continuing to contribute to the company in my ongoing position as chief science officer,” Tullis said.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases